Cargando…

Immunotherapy for Acute Myelogenous Leukaemia

One hundred and seven untreated patients with acute myelogenous leukaemia (AML) were admitted to St Bartholomew's Hospital between 10 October 1970 and 31 January 1973. Before receiving drugs to induce remission they were allocated alternatively into 2 groups to decide their remission treatment—...

Descripción completa

Detalles Bibliográficos
Autores principales:	Powles, R. L., Crowther, D., Bateman, C. J. T., Beard, M. E. J., McElwain, T. J., Russell, J., Lister, T. A., Whitehouse, J. M. A., Wrigley, P. F. M., Pike, M., Alexander, P., Fairley, G. Hamilton
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1973
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2008928/ https://www.ncbi.nlm.nih.gov/pubmed/4271320

Ejemplares similares

Immunotherapy for acute myelogenous leukaemia: a controlled clinical study 2 1/2 years after entry of the last patient.
por: Powles, R. L., et al.
Publicado: (1977)

Early central nervous system involvement in adults with acute non-myelogenous leukaemia.
por: Lister, T. A., et al.
Publicado: (1977)

Factors influencing prognosis in adults with acute myelogenous leukaemia.
por: Crowther, D., et al.
Publicado: (1975)

Further evidence of response by leukaemia patients in remission to antigen(s) related to acute myelogenous leukaemia.
por: Cocks, P., et al.
Publicado: (1977)

Adult Acute Leukaemia
por: Atkinson, K., et al.
Publicado: (1974)

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Immunotherapy alone vs no maintenance treatment in acute myelogenous leukaemia.
por: Zuhrie, S. R., et al.
Publicado: (1980)

Myelogenic Leukaemia
Publicado: (1915)

Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia
por: Dalley, C D, et al.
Publicado: (2001)

Myelogenous Leukæmia and Its Treatment
por: Debove,
Publicado: (1910)

Active immunotherapy as an adjunct to chemotherapy in the treatment of disseminated malignant melanoma: a pilot study.
por: Currie, G. A., et al.
Publicado: (1975)

Cytogenetic analysis of leukaemic colonies from acute and chronic myelogenous leukaemia.
por: Trent, J. M., et al.
Publicado: (1983)

Acquired resistance to daunorubicin in a patient with acute myelogenous leukaemia.
por: Smith, B. J., et al.
Publicado: (1976)

A quantitative analysis of heterogeneities and hallmarks in acute myelogenous leukaemia
por: Hu, C. W., et al.
Publicado: (2019)

In vitro sensitivity of clonogenic cells in resisting and relapsing patients with acute myelogenous leukaemia.
por: Marie, J. P., et al.
Publicado: (1988)

Specific active immunotherapy does not prolong survival in surgically treated patients with stage IIB malignant melanoma and may promote early recurrence.
por: Hedley, D. W., et al.
Publicado: (1978)

The Management of the Complications of Leukaemia
por: Fairley, G. Hamilton
Publicado: (1969)

OGG1 rs1052133 Polymorphism and Genetic Susceptibility to Chronic Myelogenous Leukaemia
por: Hassan, Fathelrahman M
Publicado: (2019)

Immunotherapy in leukaemia: Immunotherapy in leukaemia
por: Mu, Xingmei, et al.
Publicado: (2023)

Rationale for combination therapy of chronic myelogenous leukaemia with imatinib and irradiation or alkylating agents: implications for pretransplant conditioning
por: Topaly, J, et al.
Publicado: (2002)

Partial characterization of a membrane antigen which exhibits specificity for cells of patients with acute myelogenous leukaemia.
por: Shipman, R., et al.
Publicado: (1983)

Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia
por: Cowan-Jacob, Sandra W., et al.
Publicado: (2006)

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.
por: Perren, T. J., et al.
Publicado: (1990)

Familial platelet disorders with a predisposition to acute myelogenous leukaemia: a RUNX1 update
por: Rossini, J, et al.
Publicado: (2012)

Growth inhibitory effects of interferon on blast cells from patients with acute myelogenous leukaemia.
por: Rohatiner, A. Z.
Publicado: (1984)

Failure of short-term treatment with flurbiprofen to enhance the therapeutic effect of cyclophosphamide against rodent sarcomas and a leukaemia.
por: Heckford, S. E., et al.
Publicado: (1982)

Sensitivity of normal and acute myelogenous leukaemia marrow cells to inhibition by cytosine arabinoside.
por: Potter, C. G., et al.
Publicado: (1980)

Marrow angiogenesis-associated factors as prognostic biomarkers in patients with acute myelogenous leukaemia
por: Lee, C-Y, et al.
Publicado: (2007)

Cytogenetic & molecular analyses in adult chronic myelogenous leukaemia patients in north India
por: Anand, Maninder Singh, et al.
Publicado: (2012)

Generation of adherent lymphokine activated killer (A-LAK) cells from patients with acute myelogenous leukaemia.
por: Sedlmayr, P., et al.
Publicado: (1992)

Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
por: Dady, P. J., et al.
Publicado: (1982)

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.
por: Lakhani, S., et al.
Publicado: (1990)

Lack of prognostic value of the thymidine-labelling index in adult acute leukaemia.
por: Sewell, R. L., et al.
Publicado: (1981)

Circulating promastocytes and atypical mast cells in systemic mastocytosis associated with acute myelogenous leukaemia transformation
por: Altohami, Mohammed O. A., et al.
Publicado: (2021)

High-dose melphalan with autologous marrow for treatment of advanced neuroblastoma.
por: Pritchard, J., et al.
Publicado: (1982)

Childhood rhabdomyosarcoma: experience of the Children's Solid Tumour Group.
por: Kingston, J. E., et al.
Publicado: (1983)

Inorganic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myelogenous Leukaemia
por: Ghosn, Youssef, et al.
Publicado: (2019)

Gestational Diabetes Mellitus and Maternal Immune Dysregulation: What We Know So Far
por: McElwain, Colm J., et al.
Publicado: (2021)

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
por: Saso, R, et al.
Publicado: (2000)

Brain metastases in malignant teratoma: a review of four years' experience and an assessment of the role of tumour markers.
por: Kaye, S. B., et al.
Publicado: (1979)

Cannot write session to /tmp/vufind_sessions/sess_5rm5d2dhudt590tp0gqs4eh64v